首页 | 本学科首页   官方微博 | 高级检索  
     

常见中药复方制剂抗肝纤维化机制研究进展
引用本文:李川,吕文良. 常见中药复方制剂抗肝纤维化机制研究进展[J]. 环球中医药, 2013, 6(1): 70-73
作者姓名:李川  吕文良
作者单位:中国中医科学院广安门医院感染疾病科
摘    要:中药复方制剂具有多层次、多途径、多靶点抗肝纤维化的整体治疗优势,目前对中药复方制剂抗肝纤维化机制的研究仍然集中在通过各种途径抑制HSC增殖和活化、减少ECM的合成、加快细胞凋亡、抗脂质过氧化等方面。如何获得中药复方制剂抗肝纤维化的最大效益,需要运用细胞分子生物学、基因技术等手段对其抗肝纤维化机制进行进一步研究。

关 键 词:中药复方制剂  肝纤维化  机制

Mechanism research of common Chinese patent medicine antifibrotic
Affiliation:LI Chuan,LYU Wen-liang.Infectious Diseases Branch of Guang’anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China
Abstract:There is a advantage for Chinese patent medicine to treat hepatic fibrosis by measures of multi-level, multl-channel, multl-target. At present, antlflbrotlc mechanism research of Chinese patent medicine is still concentrated in the inhibiting HSC proliferation and activation, reducing the synthesis of ECM, accelerating cell apoptosis, resisting lipid peroxidation through a variety of channels and so on. How to get the maximum benefit of Chinese patent medicine antifibrotic requires the use of cellular and molecular biology, gene technology and other means to further study its antifibrotic mechanism.
Keywords:Chinese patent medicine  Hepatic fibrotic  Mechanism
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号